1AEA Stock Overview
A biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
argenx SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €590.00 |
| 52 Week High | €600.00 |
| 52 Week Low | €322.00 |
| Beta | 0.25 |
| 1 Month Change | 3.51% |
| 3 Month Change | 27.16% |
| 1 Year Change | 73.53% |
| 3 Year Change | 94.08% |
| 5 Year Change | n/a |
| Change since IPO | 93.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1AEA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -0.8% | 1.1% | -0.2% |
| 1Y | 73.5% | -14.5% | 7.0% |
Return vs Industry: 1AEA exceeded the German Biotechs industry which returned -14.3% over the past year.
Return vs Market: 1AEA exceeded the German Market which returned 7% over the past year.
Price Volatility
| 1AEA volatility | |
|---|---|
| 1AEA Average Weekly Movement | 4.0% |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1AEA has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 1AEA's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 1,148 | Tim Van Hauwermeiren | www.argenx.com |
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115.
argenx SE Fundamentals Summary
| 1AEA fundamental statistics | |
|---|---|
| Market cap | €36.50b |
| Earnings (TTM) | -€38.71m |
| Revenue (TTM) | €1.83b |
19.9x
P/S Ratio-943.0x
P/E RatioIs 1AEA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1AEA income statement (TTM) | |
|---|---|
| Revenue | US$1.91b |
| Cost of Revenue | US$1.19b |
| Gross Profit | US$721.98m |
| Other Expenses | US$762.27m |
| Earnings | -US$40.29m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 27, 2025
| Earnings per share (EPS) | -0.67 |
| Gross Margin | 37.83% |
| Net Profit Margin | -2.11% |
| Debt/Equity Ratio | 0.8% |
How did 1AEA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 08:28 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
argenx SE is covered by 49 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Charles Pitman-King | Barclays |
| Richard Parkes | BNP Paribas Exane |